EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma

Video content above is prompted by the following question:

1. Discuss the data presented at EHA 2024 on the efficacy and safety of teclistimab in patients with relapsed/refractory multiple myeloma (RRMM) with high-risk features: a subgroup analysis of the phase 1/2 MajesTEC-1 study. (Abstract)
   1. What was the objective of the subgroup analysis of this study?
   2. How was this study designed/what methodology was used?
   3. What results were presented?
      1. N=165
   4. N=24 aged ≥75 years
   5. N=20 ISS stage III
   6. N=38 high-risk cytogenetics
   7. N=28 extramedullary disease
   8. N=18 bone marrow plasma cells
   9. N=50 penta-drug refractory
      1. Median follow up ~30 months across subgroups
      2. Objective Response Rate (ORR)
      3. Median duration of response (mDOR)
      4. Safety